Lisata Therapeutics stock analysis
Want to see LSTA full AI Analyst Report?
Lisata Therapeutics (LSTA) Stock Price & Analysis
LSTA Stock Chart & Stats
- Day’s Range
- $1.20 - $1.26
- 52-Week Range
- $0.96 - $5.07
- Previous Close
- $1.28
- Volume
- N/A
- Average Volume (3M)
- 136.60K
- Market Cap
- $13.07M
- Enterprise Value
- $306.11M
- Total Cash (Recent Filing)
- $282.72M
- Total Debt (Recent Filing)
- $0
- Price to Earnings (P/E)
- ―
- Beta
- 0.27
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Oct 28, 2013
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Funding Runway
The approximately $225 million financing materially extends the company’s operating runway and supports advancement of MAR001/005 and MAR002 through Phase 2 milestones. This reduces immediate financing pressure and gives management more time to pursue clinical and regulatory value creation.
Low Leverage
Zero reported debt limits fixed financial obligations and reduces balance-sheet risk while the company funds clinical development. Low leverage preserves flexibility to deploy capital toward research, trials, and partnerships without adding interest costs or refinancing exposure.
Strategic Repositioning
The Marea transaction gives Lisata a broader cardioendocrine portfolio and experienced biopharmaceutical leadership, shifting the company toward Phase 2 programs with defined development milestones. That strategic reset may improve focus and strengthen execution capabilities over the medium term.
Bears Say
Persistent Cash Burn
Sustained negative operating and free cash flow shows that the business is not yet self-funding. Continued clinical investment therefore depends on external capital, making financial progress sensitive to financing needs even after the latest capital raise.
Minimal And Declining Revenue
Very small and declining revenue provides little evidence of current commercial scale or operating leverage. With revenue falling while expenses remain substantial, Lisata must rely primarily on future clinical success rather than an established revenue base to support sustainable profitability.
Dilution Risk
The acquisition financing substantially changes the ownership structure and creates potential dilution for legacy shareholders when preferred securities convert. Large equity plans and additional share issuance can also reduce each existing holder’s participation in future clinical or corporate upside.
LSTA FAQ
What was Lisata Therapeutics’s price range in the past 12 months?
What is Lisata Therapeutics’s market cap?
When is Lisata Therapeutics’s upcoming earnings report date?
How were Lisata Therapeutics’s earnings last quarter?
Is Lisata Therapeutics overvalued?
Does Lisata Therapeutics pay dividends?
What is Lisata Therapeutics’s EPS estimate?
How many shares outstanding does Lisata Therapeutics have?
What happened to Lisata Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Lisata Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Lisata Therapeutics
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David J. Mazzo
- Employees
- 21
- Website
- www.lisata.com
- Address
- 110 Allen Road, Basking Ridge, NJ, 07920, US
Lisata Therapeutics (LSTA) Earnings & Revenues
LSTA Earnings Call
Earnings Call SentimentNeutral
Lisata Therapeutics has made significant progress in its clinical programs and strategic partnerships, reflecting strong operational management and promising trial results. However, the need for additional capital for Phase III trials poses a significant challenge. The market's lack of response to positive developments highlights ongoing investor skepticism or broader market conditions.
View all LSTA earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 9 | 5 | 8 |
| Technical Analysis | 3 | 5 | 2 |
| Moving Averages | 6 | 0 | 6 |











